Minimal residual disease (MRD) monitoring in multiple myeloma (MM) relies on invasive bone marrow (BM) biopsies, which often yield insufficient tumor material. We performed whole genome sequencing of cell-free DNA from 163 plasma samples from 51 patients to develop a non-invasive MRD classifier. BM WGS identified a median of 2,502 clonal mutations, enabling cfDNA tracking at levels comparable to BM-based…
Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple Myeloma
medRxiv Oncology | | Abelman, D. D., Eagles, J., Wong, A., Shah, S., Bruce, J. P., Pedersen, S., Scott, D. S., Bonolo de Campos, C., Chow, S., Wei, E. N., Abdulsalam, S., White, D., Sandhu, I., Song, K., Braggio, E., Kumar, S., Murugesan, A., Reiman, A., Stewart, A. K., Trudel, S., Pugh, T. J.
Topics: blood-cancer, cervical-cancer, new-technology